Articles tagged with Cancer Patients
Researchers developed a new technique called proximity ligation assays (PLA) to analyze protein complexes in cancer specimens, which may aid in patient treatment decisions. By focusing on the epidermal growth factor receptor (EGFR), they discovered that patients with high amounts of EGFR protein complexes had a better prognosis when tr...
Cancer experts will discuss how to work together to accelerate progress towards a cure, expand global access to prevention, treatment, and care. The World Economic Forum is the right platform to address the urgent need for bold action.
Patients with advanced stage IV colorectal cancer are having fewer surgeries, but still showing improved survival rates due to the advent of more effective chemotherapeutic options and biologic treatments. The median survival rate for these patients has increased from 8.6% in 1988 to 17.8% in 2009.
A clinical trial found that animal-assisted therapy significantly improved the emotional well-being and quality of life of adult cancer patients. The study, published in Journal of Community and Supportive Oncology, involved 37 patients who received daily visits from certified therapy dogs during their treatment.
A new study finds that many cancer survivors experience lingering problems affecting their quality of life, including physical issues and anxiety about recurrence. The study suggests that clinicians can develop tailored interventions to address these specific concerns.
A phase II clinical trial has demonstrated that sunitinib, an FDA-approved drug, provides unprecedented antitumor activity in thymic carcinoma, a rare and aggressive tumor of the thymus gland. The study found that disease control was achieved in over 90% of patients who had failed chemotherapy.
A study has identified a new signaling pathway that generates slowly proliferating, chemo-resistant cancer cells. This pathway may offer new avenues for reducing tumor heterogeneity and improving treatment outcomes.
A study by University of Central Florida social work professor Mary Ann Burg found that cancer survivors often experience unmet needs, including physical problems like sexual dysfunction and anxiety about recurrence. The study analyzed responses from an American Cancer Society survey of 1,514 cancer survivors.
A new use of an existing antibody cocktail has been confirmed to provide key information about tumor recurrence in head and neck cancer patients. The ProExC cocktail allows pathologists to differentiate between true pre-neoplasia and reactive biopsies, enabling surgeons to make informed decisions about therapeutic interventions.
Researchers at Dartmouth Hitchcock's Norris Cotton Cancer Center developed a prognostic test for E2F4 in ER+ breast cancer, significantly predicting patient outcome regardless of treatment status. The test identifies patients who should receive aggressive follow-up treatment.
Researchers found that up to a quarter of patients with bowel cancer who have a family history could have their cancer caused by genetic mutations identified through gene testing. This could lead to improved diagnosis, treatment, and early detection for both the patient and their relatives.
Researchers have identified a novel cellular biomarker that can determine if a tumor has a potentially lethal mutation in the p53 protein, which is often referred to as the 'guardian of the genome'. The new biomarker can be used to assess p53 status in as little as 15 minutes.
Scientists discovered a small molecule, 6-thiodG, that can stop cancer cell growth and shrink tumors in mice. The compound works by disrupting the normal way cells maintain telomere length, triggering cell death.
A clinical trial combining stereotactic body radiation therapy with erlotinib improved overall and progression-free survival times for stage 4 lung cancer patients. The treatment combination increased survival rates by more than doubling, from 6-9 months to 20 months.
A recent study by UT Southwestern Medical Center researchers confirms that whole-genome sequencing can successfully identify cancer-related mutations in patients. The method was used to analyze the genomes of 258 cancer patients, detecting nearly 90% of clinically identified mutations and discovering additional cancer gene mutations.
A new study published in the Journal of Clinical Oncology found that the risk of developing leukemia after radiation therapy or chemotherapy for early-stage breast cancer is twice as high as previously reported. The study analyzed data from 20,063 breast cancer patients and found a cumulative risk of 0.5 percent.
A large study found that laparoscopic radical cystectomy leads to reliable cancer control even years after surgery, with 66% of patients free from recurrence after 5 years. The minimally invasive procedure can be as safe as open surgery for cancer control, supporting its use in bladder cancer management
University of Michigan researchers devise a reliable way to grow cancer cells from patients outside the body for study, increasing success rate to over 73% and opening doors to tailored therapies. The new technique could enable doctors to track cancer progression in real-time, making treatment decisions more informed.
Scientists have discovered that hydrogen peroxide is a key regulator of cellular functions, transmitting signals by oxidizing specific proteins. This discovery challenges previous assumptions and opens new avenues for understanding cancer development and progression.
Researchers found that two orphan receptor proteins, ERRbeta short and long forms, exert anti-cancer effects on glioblastoma cells when activated by DY131. The short form stops DNA replication, while the long form prevents cell division if DNA is already replicated.
A study published in the British Journal of General Practice found that GPs often do not refer patients for cancer investigations due to concerns about raising patient anxiety. Researchers suggest that GPs should consider discussing cancer possibilities with more openness and involve patients in the decision-making process.
A study by the University of Hawaii Cancer Center found nearly 30% of Hawaiian teens had tried e-cigarettes, with 17% using them only. The rate is three times higher than previously reported US studies. E-cigarette manufacturers' aggressive marketing and wide availability may contribute to this trend.
Researchers at Ohio State University found that patterns of molecules called long noncoding RNAs can predict response to chemotherapy and overall survival in older patients with acute myeloid leukemia. The study identified a group of 48 lncRNAs associated with survival, allowing for personalized treatment approaches.
The study found that Herceptin significantly improved 10-year survival from 75 percent to 84 percent when added to chemotherapy. Additionally, the 10-year disease-free survival rate increased from 62 percent to 74 percent with the addition of trastuzumab.
A study found that one-third of Hawaiian adolescents have tried e-cigarettes, with half having never used another tobacco product. E-cigarette users ranked somewhere between never-smokers and dual-users in terms of risk factors for smoking cigarettes.
A recent study published in Nature Communications sheds light on chromosome segregation and its impact on cancer development. Researchers discovered that mutations in the BubR1 protein can cause cancer by disrupting correct chromosomal passage.
Myriad Genetics announced new studies on its myRisk Hereditary Cancer test, detecting 105% more mutations than conventional BRCA testing. The test also showed promising results in triple negative breast cancer (TNBC) by predicting response to platinum-based therapy. Additionally, the company's BRACAnalysis molecular diagnostic test sig...
A recent study published in the Annals of Otology, Rhinology & Laryngology found that the pulsed-KTP laser treatment developed at Massachusetts General Hospital (MGH) is as effective as traditional approaches in curing patients' tumors while preserving vocal quality. The treatment has shown a high success rate of 96% among patients wit...
A study found that medical residency applicants are linguistically diverse, but their languages do not match those of the US population with limited English proficiency. The most common languages among applicants were Spanish, Hindi, French, Urdu, and Arabic.
Delayed cancer diagnoses are often caused by limitations in scientific knowledge and the delivery of healthcare, not poor professional performance. Despite this, policy initiatives focusing on GP referral times may be ineffective. Researchers advocate for better information about diagnostic challenges to improve diagnosis and care.
A phase 1 trial of ipilimumab, an immune checkpoint blocker, found clinical benefit in 45.4% of relapsed transplant patients, with notable responses in Hodgkin lymphoma and myelodysplastic syndrome. The six-month survival rate was 65%, with four patients remaining on treatment.
A study by Ohio State University researchers found that patients treated at highly-experienced radiation oncology centers had better survival rates and fewer cancer recurrences compared to those treated at less experienced centers. The study analyzed data from 470 patients treated with radiation therapy between 2002-2005.
A study at MD Anderson Cancer Center found PRM-151 to be well-tolerated in patients with advanced myelofibrosis, showing encouraging trends in clinical and histologic aspects of the disease. The therapy demonstrated reduced bone marrow fibrosis and improved hematologic parameters, suggesting potential for further development.
A Dartmouth study found that hookah smoking increased the probability of trying cigarette smoking over two years by 19%. Hookah and snus use are associated with later cigarette smoking in non-cigarette smoking adolescents and young adults. The study highlights the need for FDA regulation to restrict manufacturers' ability to flavor, pa...
A phase 2 multicenter trial of ABT-199 found encouraging results in patients with relapsed or resistant acute myelogenous leukemia, with five patients achieving eradication and several more experiencing stable disease. The oral inhibitor targets the BCL-2 protein, which is linked to resistance and poor prognosis in AML patients.
Studies presented at the ASH Annual Meeting show that immunotherapy drugs pembrolizumab and nivolumab are producing dramatic responses in Classical Hodgkin lymphoma patients. These results are promising for patients with few treatment options left, highlighting the potential of immunotherapies to work in various types of cancer.
Improvements in cancer survival mean half of all people diagnosed today will survive at least 10 years, compared to a quarter 40 years ago. However, cancers like lung, stomach, and pancreatic cancer remain extremely challenging to treat.
Scientists from Queen Mary University of London have developed a new therapy for advanced bladder cancer, showing significant tumor shrinkage in patients. The treatment, MPDL3280A, has been given breakthrough therapy designation status by the US FDA and has promising results in a phase one clinical trial.
A promising immunotherapy drug, MPDL3280A, shows improved efficacy in patients whose immune cells initially attack cancer but are shut down by PD-L1. Researchers found that tumor expression of PD-L1 in surrounding immune cells is a key indicator of response to the treatment.
A two-year study by the Stand Up To Cancer - Cancer Research Institute Immunology Translational Research Dream Team found that pembrolizumab removes PD-1, freeing up immune cells to kill cancer cells. The study validated a pathway to determine patient responsiveness and anticipated better drug combinations for more patients with melanoma.
Researchers found that metformin use was associated with a 23% decrease in mortality compared to other treatments, and may have therapeutic benefits for certain types of cancer, including breast, colorectal, lung, and prostate cancers.
The CONCORD-2 study shows extreme variations in 5-year cancer survival estimates among countries, with some countries achieving high survival rates for certain cancers. Improvements are seen in developed countries and South America, but deficiencies remain in developing countries.
Researchers at University of Cincinnati have found a Food and Drug Administration-approved therapy effective in treating older and African American patients with non-small cell lung cancer. The study suggests that gefitinib improves quality of life and outcomes for this subgroup of patients, who often face limited treatment options.
The investigational drug AG-120 has demonstrated 'extremely promising' early phase 1 clinical trial results for patients with acute myeloid leukemia (AML) harboring IDH1 mutations. This finding builds on previous phase 1 results of a related drug, AG-221, and offers hope for the treatment of this high-risk population.
CPRIT awards UTSW faculty $22.5 million for groundbreaking research into leukemia, liver cancer, and anti-cancer immunotherapy, aiming to drive innovative therapies and better care for cancer patients. The grants will support investigations targeting promising new discoveries in cancer and commercial development.
A multi-centre clinical trial suggests that a combination of three targeted drugs may be more effective than one drug for certain patients with advanced BRAF-mutated colorectal cancer. The treatment, which includes encorafenib, cetuximab, and alpelisib, showed improved efficacy and extended progression-free survival in patients.
Patients with B-cell Non-Hodgkin lymphomas and advanced solid tumors have responded to the new drug E7438, a histone methyltransferase inhibitor. The drug has shown anti-tumor effects in four patients with refractory lymphoma and one patient with a malignant rhabdoid tumor, indicating potential for personalized medical therapy.
A $7.6 million grant supports the validation of molecular tests for early detection of colorectal cancer, aiming to reduce mortality rates. The international Dream Team will focus on developing a blood test to identify patients who can benefit from chemotherapy after surgery.
Patients with advanced papillary kidney cancer respond well to a combination of bevacizumab and erlotinib, with excellent response rates and long-lasting results. The treatment shows promise for patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) who have poor prognosis.
A phase I trial of AG-120, an oral inhibitor of mutant IDH1, has shown clinical activity in patients with advanced acute myeloid leukaemia (AML) and the IDH1 mutation. The drug reduced 2-HG levels to normal, allowing cells to mature into normal functioning cells.
Researchers at Cancer Research UK have identified over 400 areas of hidden faults in the human genome, which could conceal cancer-causing gene mutations. These 'blind spots' are difficult to detect using current gene-reading technology, highlighting opportunities for new diagnostic tests and treatments.
Researchers found that older patients with Alzheimer's or cancer were less likely to receive intensive procedures at the end of life. In contrast, black patients in high-hospital-intensity regions were more likely to undergo these procedures.
Researchers at NUS and their collaborators developed a novel scoring scheme that predicts the ability of cancer cells to spread. The system monitors epithelial-mesenchymal transition (EMT) mechanism, a key process in metastasis, and has shown good correlation with previously published EMT signatures.
A collaboration between St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and Institut Curie-Inserm identified frequent mutations in genes STAG2 and TP53 that define a subtype of Ewing sarcoma associated with reduced survival. The study provides critical insights into the genetic changes that d...
A novel medical-imaging technology called TexRAD has been shown to enable early diagnosis of bowel-cancer patients not responding to standard cancer therapy. The technology analyzes the texture of tumors, distinguishing patients with good prognosis from those with poor prognosis.
A University of Colorado Cancer Center study found that TAK-733, a next-gen melanoma drug, exhibited anti-cancer activity in 10 out of 11 patient tumor samples grown in mice. The drug showed significant shrinkage in tumors up to 100%, regardless of BRAF mutation status.
A pooled analysis of five cohort studies found that smoking before first cancer diagnosis increases risk of developing a second smoking-related cancer. Smoking survivors have up to a 5-fold higher risk of developing a second primary smoking-associated cancer compared to non-smokers.
A new study reveals that informed bladder cancer patients are more motivated to quit smoking, which can prolong their lives. Physicians can significantly impact this by educating patients about the link between smoking and their disease.
Researchers found that higher volume hospital and surgeon volume are associated with fewer post-operative complications and improved overall survival for bladder cancer patients. The study aims to identify processes and interactions leading to better outcomes, which could inform improvements in care at lower volume hospitals.
A new device has been developed to visualize and differentiate between cancer cells in the bloodstream, enabling a more focused understanding of tumour properties. This technology shows promise for better diagnosis and improved patient outcomes by identifying aggressive tumours and metastatic disease.